If you are interested in the impacts of COVID-19 on those who treat and are affected by cancer, you may want to check out the winners of the 2023 DataWorks! Grand Prize. The COVID-19 & Cancer Consortium (CCC19) studies the uncertain impact of the COVID-19 pandemic on those affected by cancer. The annual award, a partnership between NIH and the Federation of American Societies for Experimental Biology (FASEB), recognizes exceptional data practices in biological and biomedical research.

CCC19 develops a robust and agile strategy to collect and disseminate vital patient information. Its approach includes three significant components:

• agile data sourcing and acquisition,
• robust data and quality management, and
• public sharing of a rapidly evolving data model.

To catalyze clinical research, CCC19 established a data sharing platform that spanned 126 cancer institutions across North America, resulting in the largest registry of its kind, with over 19,000 cases that are available for you to view.

CBIIT’s Dr. Jill Barnholtz-Sloan, a member of CCC19’s scientific executive committee, says, “I congratulate CCC19 on their remarkable achievement in winning the NIH/FASEB’s DataWorks! Prize. Since its start in 2020, CCC19 has made significant progress in our understanding of how COVID-19 impacts individuals with cancer. This important collaboration brings together more than 120 cancer centers to facilitate data sharing, and I hope our efforts of streamlining data collection and analysis will continue to accelerate data sharing practices in our field.”

CCC19’s transparent and streamlined approach to data management highlights the significance of data sharing practices in advancing scientific discovery and human health. By making all results immediately publicly accessible and sharing data on demand, CCC19 demonstrated the power of collaborative efforts to tackle complex issues and provide valuable insights that can help improve patient care outcomes and accelerate scientific progress.